Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product
Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M.-L., Kmiecik, T. E., Vande Woude, G. F., & Aaronson, S. A. (1991) · Science · doi:10.1126/science.1846706 · Cited by 2,236
Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud
Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A., & Birchmeier, C. (1995) · Nature · doi:10.1038/376768a0 · Cited by 1,284
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
Bischoff, J. R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3052 · Cited by 1,216
The implications of angiogenesis for the biology and therapy of cancer metastasis
Fidler, I. (1994) · Cell · doi:10.1016/0092-8674(94)90187-2 · Cited by 1,098
Novel mutations of the MET proto-oncogene in papillary renal carcinomas
Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., Lubensky, I., Neumann, H. P., Brauch, H., Decker, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202547 · Cited by 497
Tyrosine kinase receptor indistinguishable from the c-met protein
Giordano, S., Ponzetto, C., Renzo, M. F. D., Cooper, C. S., & Comoglio, P. M. (1989) · Nature · doi:10.1038/339155a0 · Cited by 490
Self-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456
Activating mutations for the Met tyrosine kinase receptor in human cancer
Jeffers, M., Schmidt, L., Nakaigawa, N., Webb, C. P., Weirich, G., Kishida, T., Zbar, B., & Vande Woude, G. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11445 · Cited by 442
Rong, S., Segal, S., Anver, M., Resau, J. H., & Vande Woude, G. F. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4731 · Cited by 363
Cited by
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Targeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3205 · Cited by 1,423
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Self-citationDrug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 818
Self-citationZou, H. Y., Li, Q., Lee, J. H., Arango, M. E., McDonnell, S. R., Yamazaki, S., Koudriakova, T. B., Alton, G., Cui, J. J., Kung, P.-P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4443 · Cited by 745
Scatter-factor and semaphorin receptors: cell signalling for invasive growth
Trusolino, L., & Comoglio, P. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc779 · Cited by 745
Self-citationTumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Invasive growth: a MET-driven genetic programme for cancer and stem cells
Boccaccio, C., & Comoglio, P. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1912 · Cited by 538
Self-citationc-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
Christensen, J. G., Burrows, J., & Salgia, R. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.09.044 · Cited by 513
c-Met: Structure, functions and potential for therapeutic inhibition
Ma, P. C., Maulik, G., Christensen, J., & Salgia, R. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023768811842 · Cited by 504
Hypoxic gene expression and metastasis
Le, Q.-T., Denko, N. C., & Giaccia, A. J. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031768.89246.d7 · Cited by 468
Targeting the c-Met Signaling Pathway in Cancer
Peruzzi, B., & Bottaro, D. P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0818 · Cited by 448
The Semaphorin 4D receptor controls invasive growth by coupling with Met
Giordano, S., Corso, S., Conrotto, P., Artigiani, S., Gilestro, G., Barberis, D., Tamagnone, L., & Comoglio, P. M. (2002) · Nature Cell Biology · doi:10.1038/ncb843 · Cited by 444
Self-citationA Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive Growth
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2001) · Cell · doi:10.1016/s0092-8674(01)00567-0 · Cited by 420
Self-citationMet receptor tyrosine kinase: enhanced signaling through adapter proteins
Furge, K. A., Zhang, Y.-W., & Vande Woude, G. F. (2000) · Oncogene · doi:10.1038/sj.onc.1203859 · Cited by 410
Mellman, I., & Yarden, Y. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016949 · Cited by 394
Maulik, G., Shrikhande, A., Kijima, T., Ma, P. C., Morrison, P. T., & Salgia, R. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00029-6 · Cited by 391
Receptor tyrosine kinase signalling as a target for cancer intervention strategies.
Zwick, E., Bange, J., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080161 · Cited by 384
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
Comoglio, P. M., Trusolino, L., & Boccaccio, C. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0002-y · Cited by 381
Self-citationQian, F., Engst, S., Yamaguchi, K., Yu, P., Won, K.-A., Mock, L., Lou, T., Tan, J., Li, C., Tam, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4889 · Cited by 350
“hepatocellular (7), head and neck (8), and ovarian (9) carcinomas, and in other tumor types including small cell lung cancer (10),”
BackgroundProperties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Roskoski, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105463 · Cited by 335
Onozato, R., Kosaka, T., Kuwano, H., Sekido, Y., Yatabe, Y., & Mitsudomi, T. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181913e0e · Cited by 327
The Met tyrosine kinase receptor in development and cancer
Gentile, A., Trusolino, L., & Comoglio, P. M. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9107-6 · Cited by 319
Self-citationAnaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Roskoski, R. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.007 · Cited by 303
Expression and mutational analysis of MET in human solid cancers
Ma, P. C., Tretiakova, M. S., MacKinnon, A. C., Ramnath, N., Johnson, C., Dietrich, S., Seiwert, T., Christensen, J. G., Jagadeeswaran, R., Krausz, T., et al. (2008) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20604 · Cited by 300
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor
Michieli, P., Mazzone, M., Basilico, C., Cavassa, S., Sottile, A., Naldini, L., & Comoglio, P. M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.032 · Cited by 299
Self-citationWang, R., Ferrell, L. D., Faouzi, S., Maher, J. J., & Bishop, J. M. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.153.5.1023 · Cited by 281
MET: a promising anticancer therapeutic target
Peters, S., & Adjei, A. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.71 · Cited by 280
Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
Blumenschein, G. R., Mills, G. B., & Gonzalez-Angulo, A. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3774 · Cited by 273
Seiwert, T. Y., Jagadeeswaran, R., Faoro, L., Janamanchi, V., Nallasura, V., El Dinali, M., Yala, S., Kanteti, R., Cohen, E. E. W., Lingen, M. W., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2881 · Cited by 269
MET: A Critical Player in Tumorigenesis and Therapeutic Target
Graveel, C. R., Tolbert, D., & Vande Woude, G. F. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009209 · Cited by 128
“1B) (Donate et al. 1994).”
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
Papaccio, F., Della Corte, C. M., Viscardi, G., Di Liello, R., Esposito, G., Sparano, F., Ciardiello, F., & Morgillo, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113595 · Cited by 110
Kato, T. (2017) · Biomedical Reports · doi:10.3892/br.2017.1001 · Cited by 49
“HGF‐Tg mice made using the albumin promoter exhibit a lower expression level of HGF when compared with HGF-Tg mice made using the metallothionein promoter, with a smaller increase in liver size (62,63).”
Metadata
- Authors
- Di Renzo, M. F., Olivero, M., Martone, T., Maffe, A., Maggiora, P., De Stefani, A., Valente, G., Giordano, S., Cortesina, G., & Comoglio, P. M.
- Venue
- Oncogene
- Published
- 2000-03-16
- Volume
- 19
- Issue
- 12
- Pages
- 1547-1555
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2005092992
- Cited by
- 332
- References
- 27
- FWCI
- 13.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.